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Abstract
Background: A factor-based coagulation management following major trauma is recommended as standard of
care by the European Trauma Treatment Guidelines. However, concerns about the thromboembolic risk of this
approach are still prevalent. Our study therefore aims to assess if such a haemostatic management is associated
with an increased risk for thromboembolic events.
Methods: In this retrospective observational study carried out at the University Hospital Zurich we compared two
three-year periods before (period 1: 2005–2007) and after (period 2: 2012–2014) implementation of a factor-based
coagulation algorithm. We included all adult patients following major trauma primarily admitted to the University
Hospital Zurich. Thromboembolic events were defined as a new in-hospital appearance of any peripheral
thrombosis, arterial embolism, pulmonary embolism, stroke or myocardial infarction. A logistic regression was
performed to investigate the association of thromboembolic events with possible confounders such as age, sex,
specific Abbreviated Injury Scale (AIS) subgroups, allogeneic blood products, and the coagulation management.
Results: Out of 1138 patients, 772 met the inclusion criteria: 344 patients in period 1 and 428 patients in period 2.
Thromboembolic events were present in 25 patients (7.3%) of period 1 and in 42 patients (9.8%) of period 2 (raw
OR 1.39, 95% CI 0.83 to 2.33, p = 0.21). Only AIS extremities (adjusted OR 1.26, 95% CI 1.05 to 1.52, p = 0.015) and
exposure to allogeneic blood products (adjusted OR 2.39, 95% CI 1.33 to 4.30, p = 0.004) were independently
associated with thromboembolic events in the logistic regression, but the factor-based coagulation management
was not (adjusted OR 1.60, 95% CI 0.90–2.86, p = 0.11).
Conclusion: There is no evidence that a goal-directed, factor-based coagulation management is associated with an
increased risk for thromboembolic events following major trauma.
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Background
A goal-directed, factor-based coagulation management
following major trauma is recommended as standard of
care by the European Trauma Treatment Guidelines to
treat and prevent trauma induced coagulopathy [1]. Such
individualized coagulation management needs to be
guided by viscoelastic testing and laboratory values [2, 3]
to meet patients’ demands and is therefore more com-
plex than traditional transfusion strategies of red blood
cells (RBC), fresh frozen plasma (FFP) and platelet con-
centrates (PC) at fixed ratios [4]. Predefined coagulation
algorithms were introduced to tackle this issue and to
guide the haemostatic management of clinicians at the
emergency department [5, 6]. Such coagulation algo-
rithms were proven to reduce the incidence of massive
transfusion [7], the transfusion of allogeneic blood prod-
ucts [3, 5, 7] and to improve survival rate [6] of patients
following major trauma. Beneficial effects of a factor-
based coagulation management have been reported for
patients following trauma, as well as in the early identifi-
cation and individualized treatment of coagulopathy in
major obstetric haemorrhage [8]. Moreover, in patients
undergoing cardiac surgery a point of care coagulation
management reduced the exposure to allogeneic blood
products, lowered the re-exploration rate and decreased
the incidence of postoperative acute kidney injury as
well as thromboembolic events [9]. It was shown that a
goal-directed factor concentrate based coagulation and
transfusion management compared to a fixed ratio
transfusion approach reduced the incidence of massive
transfusion and the exposure of patients to allogeneic
blood products [3, 7]. Moreover, 24 h and in-hospital
mortality were significantly reduced [7]. However, con-
cerns do remain about the thromboembolic risk of the
factor-based resuscitation approach in trauma patients.
Our study therefore aims to assess if such a haemo-
static management is associated with an increased risk
for thromboembolic events following major trauma.
Methods
Study design & participants
We conducted a retrospective cohort study comparing
two time periods with different transfusion and coagula-
tion management strategies of trauma patients in a sin-
gle, tertiary care hospital with a level-1 trauma centre.
As changes to the transfusion and coagulation manage-
ment protocol were gradually implemented from 2008
until 2012, we investigated two three-year periods: The
first from 2005 until 2007 before and the second one
after the implementation from 2012 until 2014. In these
two periods we included all severely injured trauma pa-
tients aged ≥16 with an injury severity score (ISS) ≥ 16,
who were primarily admitted to the University Hospital
of Zurich in Switzerland. We excluded patients with
missing or incomplete records as well as patients re-
ferred from another hospital.
This study was approved by the local ethics committee
(KEK-ZH 2015–0309) and follows the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) recommendations for cohort studies.
Setting
As one of the 12 level-1 trauma centres in Switzerland,
the University Hospital Zurich treats trauma patients in a
highly standardized approach. Specific measures were in-
troduced in the time between the two analysed cohorts.
The goal-directed and factor concentrate based coagula-
tion algorithm was used for transfusion and coagulation
management in the latter period while in the first period,
RBC, FFP and PC were transfused without a goal-directed
management. The transfusion and coagulation algorithm
is a stepwise guidance for the treatment of all bleeding pa-
tients in the University Hospital Zurich and has been de-
scribed previously in detail by Stein et al. [7]. In period 2,
tranexamic acid was applied empirically to patients at risk
of significant bleeding analogue to the CRASH-2 trial.
One gram of tranexamic acid was given already at the
scene of injury or on admission to emergency department.
Additional doses of tranexamic acid were evaluated only
after viscoelastic proof of hyperfibrinolysis. In addition to
transfusion and coagulation management, further mea-
sures like primary whole-body CT scan upon admission,
damage-control surgery, restrictive fluid resuscitation with
crystalloids and concepts of permissive hypotension were
also introduced between the two periods. Guidelines on
thrombosis prophylaxis were equivalent between the two
periods. Standard thrombosis prophylaxis at the Univer-
sity Hospital Zurich includes the application of low-
molecular-weight or unfractionated heparin as soon as the
bleeding is controlled. Intermittent pneumatic compres-
sion devices were applied in case of contraindication to
anticoagulant medication.
An internal trauma database and the anaesthesia pro-
tocols (from hospital admission to the intensive care
unit) provided information about patient characteristics,
injury patterns, applied allogeneic blood products (RBC,
FFP and PC), coagulation management (fibrinogen, four-
factor prothrombin complex concentrate (PCC), coagu-
lation factor XIII, in-hospital tranexamic acid use) and
laboratory values. In addition, all radiology reports and
all discharge summaries were screened for the diagnosis
of any thromboembolic event (peripheral thrombosis, ar-
terial embolism, pulmonary embolism, stroke, or myo-
cardial infarction) during hospitalization.
Outcomes
Thromboembolic events were defined as a new in-hospital
appearance of any peripheral thrombosis, arterial embolism,
Stein et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine          (2019) 27:117 Page 2 of 7
pulmonary embolism, stroke or myocardial infarction. The
primary outcome was the incidence of thromboembolic
events in both observation periods and the identification of
potential confounders.
Statistics
Demographics were displayed as means and standard de-
viations (SD) or counts (n) and proportions (%). Univari-
able binomial logistic regressions were calculated for raw
odds ratios (OR). A multivariable binomial logistic re-
gression model was fitted to ascertain the effects of age,
sex, specific Abbreviated Injury Scale (AIS) subgroups
(head, thorax, abdomen and extremities), allogeneic
blood products, and the coagulation algorithm on the
likelihood that patients suffer from any thromboembolic
event. The model fit was assessed using the Hosmer-
Lemeshow test. A p-value of ≤0.05 was used to define
statistical significance. All statistical analyses were per-
formed using SPSS version 25 (IBM Corp., Armonk, NY,
USA).
Results
We screened 1138 eligible patients (age ≥ 16 years) in
period 1 (2005–2007) and period 2 (2012–2014) of
which 355 patients were excluded because they were re-
ferred from another hospital and 11 patients because of
missing emergency department records. The remaining
772 patients were analysed: 344 patients in period 1 and
428 patients in period 2 (Fig. 1). Epidemiologic, demo-
graphic and treatment data are presented in Table 1.
With the implementation of the coagulation algorithm,
allogeneic blood transfusions were reduced and the use
of factor concentrates increased: 181 (53%) of the
patients in period 1 were exposed to any allogeneic
blood product transfusion, while only 140 (33%) of the
patients were transfused in period 2. The administration
of tranexamic acid, four-factor PCC, and coagulation
factor XIII increased from 0.9 to 50%, from 4.4 to 9.1%
and from 0 to 12% of patients, respectively. Details on
the percentage of coagulation factor and blood product
use are presented in Table 1.
During period 1, 25 (7.3%) of the patients had a
thromboembolic event compared to 42 (9.8%) of the pa-
tients in period 2 (raw OR 1.39, 95% CI 0.83–2.33, p =
0.21). The detailed comparison of thromboembolic
events making up the primary composite outcome are
summarized in Table 2 for both periods.
The logistic regression model explained 9.0% (Nagelk-
erke R2) of the variance in thromboembolic events. Of
the nine predictor variables only two were statistically
significant: Injury to the extremities (adj. OR 1.26, 95%
CI 1.05 to 1.52, p = 0.015) and transfusion of any allo-
geneic blood product (adj. OR 2.39, 95% CI 1.33 to 4.30,
p = 0.004, Table 3). The period after the implementation
of the goal-directed factor-based coagulation algorithm
was not associated with the dependent variable (adj. OR
1.60, 95% CI 0.90–2.86, p = 0.11).
Discussion
Comparing two periods with a different coagulation
management, we found no evidence of increased
thromboembolic risk due to a goal-directed, factor-based
coagulation algorithm in contrast to haemostatic therapy
by means of fixed ratio transfusion of allogeneic blood
products. The incidence of the composite outcome of
peripheral thrombosis, arterial embolism, pulmonary
embolism, stroke, or myocardial infarction did not differ
significantly between the two periods. Further, in a mul-
tivariable logistic regression adjusting for confounders a
factor-based coagulation management period was not as-
sociated with an increased risk of thromboembolic
events. To the best of our knowledge, this is the first
study investigating the impact of a goal-directed factor-
based coagulation management on thromboembolic
events following major trauma.
Haemostatic resuscitation was traditionally performed
by transfusion of RBC, FFP and PC at a fixed ratio [4, 10].
Allogeneic blood transfusions are associated with several
adverse events (e.g. infections, volume overload, immuno-
suppression and kidney injury) [11–14] and it has been
shown that a reduced transfusion requirement improved
clinical outcomes including mortality [15, 16]. Therefore,
a factor-based, goal-directed coagulation management
guided by viscoelastic point of care tests [2] has been
proposed as a new approach of haemostatic resuscitation
[1, 7, 17–19]. This coagulation management was proven
to decrease transfusion requirement with beneficial
Major trauma patients (ISS 16)
admitted to the University Hospital Zurich
in 2005-2007 and 2012-2014
n=1138
 Excluded: n=366
  - 355 referred from another hospital
  - 11 incomplete medical records
Eligible for analysis
n=772
2005-2007
n=344
2012-2014
n=428
Fig. 1 Flowchart of patient selection during the observation period.
ISS = Injury Severity Score
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outcomes in trauma patients [1, 7, 17, 18]. The key elem-
ent of the algorithm is the administration of coagulation
factors according to an individualized goal-directed ap-
proach based on viscoelastic and laboratory assessment. In
our study, period 1 represents the traditional haemostatic
management by transfusion of blood products at a fixed
ratio. As shown in Table 1, fibrinogen and PCC were also
administered in this period but not in a goal-directed fash-
ion guided by viscoelastic testing.
In period 2, after the full implementation, the coagula-
tion and transfusion algorithm was used as the new stand-
ard to guide haemostatic therapy. This provides early
detection of low fibrinogen levels, low platelet count and
the detection of hyperfibrinolysis, all of which can be
treated immediately in order to prevent or manage trauma
induced coagulopathy [20–24]. Tranexamic acid was used
empirically in patients at risk of significant bleeding as in-
vestigated in the CRASH-2 trial and not only when hyper-
fibrinolysis was evident in viscoelastic testing. Since 2013
tranexamic acid was applied to patients already at the
scene of injury before reaching the hospital, so our re-
ported (in-hospital) incidence may well be underesti-
mated. This haemostatic approach is a key element in the
treatment of major trauma patients and recommended by
the European Trauma Treatment Guidelines [1].
Table 1 Patients’ characteristics for the period before (Period 1, 2005–2007) and after (Period 2, 2012–2014) the implementation of a
goal-directed factor-based coagulation algorithm. Values are means with standard deviations or counts and proportions
Period 1 (2005–2007)
n = 344
Period 2 (2012–2014)
n = 428
Age - years 42.0 (19.0) 51.5 (21.8)
Sex - male 268 (78%) 315 (74%)
Penetrating trauma 29 (8.4%) 16 (3.7%)
Injury severity score 33 (13) 34 (19)
AIS head 3 (2) 3 (2)
AIS thorax 2 (2) 2 (2)
AIS abdomen 1 (2) 1 (1)
AIS extremities 1 (1) 1 (2)
Laboratory values
Haemoglobin - g/L 111 (29) 107 (53)
Platelet count on entry - 103/mcL 211 (68) 198 (81)
Base Excess on entry - mmol/L −4.7 (4.6) −4.4 (5.0)
Lactate on entry - mmol/L 3.2 (2.4) 2.6 (2.4)
Fibrinogen on entry - g/L 1.9 (0.8) 2.2 (0.9)
INR on hospital admission 1.26 (0.5) 1.34 (0.5)
Coagulation factors and allogeneic blood products
In-hospital TXA 3 (0.9%) 209 (50%)
Fibrinogen 130 (38%) 138 (32%)
PCC 15 (4.4%) 39 (9.1%)
Factor XIII 0 53 (12%)
Transfusion of any allogeneic blood product 181 (53%) 140 (33%)
RBC 175 (51%) 113 (26%)
PC 56 (16%) 66 (15%)
FFP 122 (36%) 67 (16%)
AIS Abbreviated Injury Scale, RBC Red Blood Cell, PC Platelet Concentrate, FFP Fresh Frozen Plasma, PCC Prothrombin Complex Concentrate, TXA Tranexamic Acid
Table 2 Incidence of different thromboembolic events and
their primary composite endpoint for the period before (Period
1, 2005–2007) and after (Period 2, 2012–2014) implementation
of a goal-directed factor-based coagulation algorithm
Period 1 (2005–2007)
n = 344
Period 2 (2012–2014)
n = 428
Peripheral thrombosis 16 (4.7%) 30 (7.0%)
Arterial embolism 3 (0.9%) 1 (0.2%)
Pulmonary embolism 6 (1.7%) 11 (2.6%)
Stroke 1 (0.3%) 2 (0.5%)
Myocardial infarction 0 5 (1.2%)
Thromboembolic events 25 (7.3%) 42 (9.8%)
Values are counts and proportions
Stein et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine          (2019) 27:117 Page 4 of 7
Frequency of thrombotic complications in trauma pa-
tients was reported in 1.1% up to 34.3% [25–27]. Our in-
cidence of thromboembolic events was below 10% in
both periods and thereby in the lower range. There are
many possible confounders explaining this broad range
of reported incidence. In the era of ultrasound, more
thromboembolic events are discovered - occasionally
even in asymptomatic patients [28]. Therefore, we as-
sume that the incidence of thromboembolism of period
1 in our study might even be underestimated. Another
confounder is the trauma mechanism. While in Europe
most patients suffer from blunt injuries, penetrating in-
juries are leading in the United States [29]. Fractures of
extremities are a well-known risk factor for venous
thromboembolism. Especially patients suffering from
pelvic fractures have a very high risk to develop deep
venous thrombosis despite mechanical and pharmaceut-
ical thromboprophylaxis [30]. Consequently, the four
AIS subgroups (head, extremities, thorax, abdomen)
were chosen to select an adequate number of confound-
ing variables with clinical relevance in regard to the risk
of thrombosis. In our multivariable analysis, injuries to
extremities were independently associated with the pri-
mary outcome. In addition, exposure to allogeneic blood
products also proved to be an independent risk factor
for thromboembolic events in trauma patients. That
finding is congruent to recently published data of
750.937 patients undergoing surgery showing an associ-
ation of perioperative RBC transfusion with venous
thromboembolism [31]. Major trauma patients suffer
from extended soft tissue injury and subsequent inflam-
matory response leading to a diffuse activation of coagu-
lation factors, which culminates in a hypercoagulable
state in the post-aggression phase [32]. While this alone
increases the risk of developing venous thromboembol-
ism during hospitalization, trauma patients are further
exposed to numerous additional risk factors, like pro-
longed immobilization and a restrictive antithrombotic
prophylaxis in case of a traumatic brain injury.
Several limitations regarding our study should be con-
sidered in interpreting our findings. Foremost, this was a
retrospective observational study and is bound by the in-
herent limitations of its design. In this sense, we can
only deduct association and not causation. Further, there
may be some confounders which we cannot detect and
correct retrospectively. To limit this, we calculated mul-
tivariable models adjusting for possible confounders.
Variables of our multivariable regression model were
chosen for clinical reasons in order to represent known
confounders influencing the incidence of thrombo-
embolic events. Confounders were not selected accord-
ing to a stepwise variable selection. Additionally,
retrospective studies are confined by the amount of
available data, impeding sampling for adequate power.
Especially in the current study, as we do not have a pre-
specified equivalence margin, we can only state that we
found no evidence for an increased thromboembolic
risk, but we cannot definitively exclude a possible effect.
Due to the low count of thromboembolic events, we
were limited in the analysis to identify confounders in
more detail. Future studies are encouraged to build on
our work to investigate single factors in more detail.
Conclusion
There is no evidence that a goal-directed, factor-based
coagulation management is associated with an increased
risk for thromboembolic events following major trauma.
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